Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Monotherapy for Patients With Newly Diagnosed Partial-onset Seizures: a Double-blind, Randomized, Active-controlled, Parallel-group, Multicenter Clinical Study - Open-label ESL Extension

Next Previous
X
Search
Trial Profile

Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Monotherapy for Patients With Newly Diagnosed Partial-onset Seizures: a Double-blind, Randomized, Active-controlled, Parallel-group, Multicenter Clinical Study - Open-label ESL Extension

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 29 Dec 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Eslicarbazepine acetate (Primary)
  • Indications Partial epilepsies
  • Focus Therapeutic Use
  • Sponsors Bial

    • Most Recent Events

    • 22 Apr 2021 Results of post hoc analysis from NCT02484001 and NCT01162460; evaluating the lipid changes in adult patients with newly diagnosed focal-onset seizures, presented at the 73rd Annual Meeting of the American Academy of Neurology
    • 17 Sep 2020 Results published in the Epilepsia
    • 01 May 2020 Results evaluating efficacy and safety of Eslicarbazepine acetate (ESL) monotherapy during long-term treatment presented at the 72nd Annual Meeting of the American Academy of Neurology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top